{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T22:38:11Z","timestamp":1782772691124,"version":"3.54.5"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Millions of children in the United States have been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), with many infections leading to hospitalization. For pediatric patients, especially younger children, treatment options are limited. Remdesivir has demonstrated a positive safety and efficacy profile in adults, but little data is published regarding remdesivir use in pediatric patients. Additional data for SARS-CoV-2 treatments in pediatric patients is required to prevent further SARS-CoV-2\u2013related morbidity and mortality. At a single pediatric academic medical center, the safety and efficacy of remdesivir was evaluated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A retrospective review of patients admitted to a pediatric academic medical center who received remdesivir over a 17-month period was completed. All pediatric patients who received at least 1 dose of remdesivir were included. Safety and efficacy were assessed using national organization\u2019s definitions of clinical improvement, bradycardia, hypertension, acute kidney injury and drug-induced liver injury.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>There were 48 pediatric patients included in this study with 29% of patients admitted to the pediatric intensive care unit. Less than one-third of patients received the full treatment course of remdesivir, with over half of patients not completing therapy due to symptomatic improvement or hospital discharge. Majority of patients required some level of supplemental oxygen support. The median World Health Organization score was consistent throughout all 5 days of therapy. No patients experienced significant bradycardia, hypertension, acute kidney injury, or drug-induced liver injury.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Remdesivir may correlate with clinical stability or improvement and demonstrates safety when used in pediatric patients. A randomized controlled trial is needed to confirm these findings.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000003814","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T16:33:33Z","timestamp":1675355613000},"page":"310-314","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":18,"title":["Remdesivir Use in Pediatric Patients for SARS-CoV-2 Treatment: Single Academic Center Study"],"prefix":"10.1097","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3020-0727","authenticated-orcid":false,"given":"Allison M.","family":"Samuel","sequence":"first","affiliation":[{"name":"Department of Pharmacy, University of Wisconsin Health, Madison, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa L.","family":"Hacker","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Wisconsin Health, Madison, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Zebracki","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Wisconsin Health, Madison, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica C.","family":"Bogenschutz","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Wisconsin Health, Madison, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Schulz","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Wisconsin Health, Madison, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Strayer","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Wisconsin Health, Madison, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua P.","family":"Vanderloo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Wisconsin Health, Madison, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pelin","family":"Cengiz","sequence":"additional","affiliation":[{"name":"Division of Pediatric Critical Care Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheryl","family":"Henderson","sequence":"additional","affiliation":[{"name":"Division of Pediatric Infectious Diseases, Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,12,29]]},"reference":[{"key":"R2-20250614","doi-asserted-by":"crossref","first-page":"e215298","DOI":"10.1001\/jamanetworkopen.2021.5298","article-title":"Characteristics and disease severity of US children and adolescents diagnosed with COVID-19.","volume":"4","author":"Preston","year":"2021","journal-title":"JAMA Netw Open"},{"key":"R3-20250614","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19 \u2013 final report.","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"R6-20250614","doi-asserted-by":"crossref","first-page":"791.e5","DOI":"10.1016\/j.cmi.2021.02.013","article-title":"Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns.","volume":"27","author":"Touafchia","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"R8-20250614","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/jpids\/piab123","article-title":"A description of COVID-19-directed therapy in children admitted to US intensive care units 2020.","volume":"11","author":"Schuster","year":"2022","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R9-20250614","doi-asserted-by":"crossref","first-page":"e2020047803","DOI":"10.1542\/peds.2020-047803","article-title":"Compassionate use of remdesivir in children with severe COVID-19.","volume":"147","author":"Goldman","year":"2021","journal-title":"Pediatrics"},{"key":"R11-20250614","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/jpids\/piaa045","article-title":"Multicenter initial guidance on use of antivirals for children with coronavirus disease 2019\/severe acute respiratory syndrome coronavirus 2.","volume":"9","author":"Chiotos","year":"2020","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R14-20250614","doi-asserted-by":"crossref","first-page":"e20171904","DOI":"10.1542\/peds.2017-1904","article-title":"Clinical practice guideline for screening and management of high blood pressure in children and adolescents.","volume":"140","author":"Flynn","year":"2017","journal-title":"Pediatrics"},{"key":"R15-20250614","doi-asserted-by":"crossref","first-page":"c179","DOI":"10.1159\/000339789","article-title":"KDIGO clinical practice guidelines for acute kidney injury.","volume":"120","author":"Khwaja","year":"2012","journal-title":"Nephron Clin Pract"},{"key":"R16-20250614","doi-asserted-by":"crossref","first-page":"878","DOI":"10.14309\/ajg.0000000000001259","article-title":"ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury.","volume":"116","author":"Chalasani","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"R17-20250614","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa2116846","article-title":"Early remdesivir to prevent progression to severe COVID-19 in outpatients.","volume":"386","author":"Gottlieb","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003814","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T00:05:39Z","timestamp":1749945939000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,29]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000003814","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12,29]]}}}